VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling

Circulation Research

Volumn 107, Issue 3, 2010, Pages 408-417

  Zhang, Jiasheng ^a,f   Silva, Teresa ^a,f   Yarovinsky, Timur ^b,d   Manes, Thomas D ^d   Tavakoli, Sina ^a   Nie, Lei ^a,f   Tellides, George ^c,f   Pober, Jordan S ^d,e   Bender, Jeffrey R ^b,d,e   Sadeghi, Mehran M ^a,f  

^a Cardiovascular Molecular Imaging Laboratory   (United States)

^b Division of Cardiovascular Medicine   (United States)

^c Section of Cardiovascular Medicine   (United States)

^d Section of Immunobiology   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Bevacizumab; T lymphocytes; Transplantation; Vascular endothelial growth factor; Vascular remodeling

Indexed keywords

ALPHA ACTIN; BEVACIZUMAB; GAMMA INTERFERON; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; RECOMBINANT INTERCELLULAR ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; ANGIOGENESIS INHIBITOR; CD3 ANTIGEN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY ENDOTHELIUM; ARTERY GRAFT; ARTICLE; CD3+ T LYMPHOCYTE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIUM CELL; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTIMA; LEUKEMIA CELL LINE; LEUKOCYTE ACTIVATION; LYMPHOCYTE MIGRATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SCID MOUSE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VASCULAR DISEASE; VASCULAR REMODELING; ANIMAL; ARTERY; CORONARY BLOOD VESSEL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOLOGY; LYMPHOCYTE; MOUSE MUTANT; PHYSIOLOGY; T LYMPHOCYTE; TRANSPLANTATION; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ARTERIES; CORONARY VESSELS; HUMANS; JURKAT CELLS; LYMPHOCYTES; MICE; MICE, SCID; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; T-LYMPHOCYTES; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956633519     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.109.210963     Document Type: Article

References (48)

1. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581-611. (Pubitemid 39099316)
2. Shiojima I, Walsh K. The role of vascular endothelial growth factor in restenosis: the controversy continues. Circulation. 2004;110:2283-2286. (Pubitemid 39407327)
3. Asahara T, Bauters C, Pastore C, Kearney M, Rossow S, Bunting S, Ferrara N, Symes JF, Isner JM. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation. 1995;91:2793-2801.
4. Lemstrom KB, Krebs R, Nykanen AI, Tikkanen JM, Sihvola RK, Aaltola EM, Hayry PJ, Wood J, Alitalo K, Yla-Herttuala S, Koskinen PK. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation. 2002;105:2524-2530.
5. Hutter R, Carrick FE, Valdiviezo C, Wolinsky C, Rudge JS, Wiegand SJ, Fuster V, Badimon JJ, Sauter BV. Vascular endothelial growth factor regulates reendothelialization and neointima formation in a mouse model of arterial injury. Circulation. 2004;110:2430-2435.
6. Khurana R, Zhuang Z, Bhardwaj S, Murakami M, De Muinck E, Yla-Herttuala S, Ferrara N, Martin JF, Zachary I, Simons M. Angiogenesisdependent and independent phases of intimal hyperplasia. Circulation. 2004;110:2436-2443.
7. Walter DH, Cejna M, Diaz-Sandoval L, Willis S, Kirkwood L, Stratford PW, Tietz AB, Kirchmair R, Silver M, Curry C, Wecker A, Yoon YS, Heidenreich R, Hanley A, Kearney M, Tio FO, Kuenzler P, Isner JM, Losordo DW. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation. 2004;110:36-45.
8. Ohtani K, Egashira K, Hiasa K, Zhao Q, Kitamoto S, Ishibashi M, Usui M, Inoue S, Yonemitsu Y, Sueishi K, Sata M, Shibuya M, Sunagawa K. Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells. Circulation. 2004;110:2444-2452.
9. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391-400.
10. Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C, Fuh G, Lowman H, Ferrara N. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci. 2008;49:522-527.
11. Lorber MI, Wilson JH, Robert ME, Schechner JS, Kirkiles N, Qian HY, Askenase PW, Tellides G, Pober JS. Human allogeneic vascular rejection after arterial transplantation and peripheral lymphoid reconstitution in severe combined immunodeficient mice. Transplantation. 1999;67:897-903.
12. Sadeghi MM, Esmailzadeh L, Zhang J, Guo X, Asadi A, Krassilnikova S, Fassaei HR, Luo G, Al-Lamki RS, Takahashi T, Tellides G, Bender JR, Rodriguez ER. ESDN is a marker of vascular remodeling and regulator of cell proliferation in graft arteriosclerosis. Am J Transplant. 2007;7:2098-2105.
13. Wang Y, Burns WR, Tang PC, Yi T, Schechner JS, Zerwes HG, Sessa WC, Lorber MI, Pober JS, Tellides G. Interferon-gamma plays a nonredundant role in mediating T cell-dependent outward vascular remodeling of allogeneic human coronary arteries. Faseb J. 2004;18:606-608.
14. Tellides G, Tereb DA, Kirkiles-Smith NC, Kim RW, Wilson JH, Schechner JS, Lorber MI, Pober JS. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature. 2000;403:207-211. (Pubitemid 30050965)
15. Burns WR, Wang Y, Tang PC, Ranjbaran H, Iakimov A, Kim J, Cuffy M, Bai Y, Pober JS, Tellides G. Recruitment of CXCR3+ and CCR5+ T cells and production of interferon-gamma-inducible chemokines in rejecting human arteries. Am J Transplant. 2005;5:1226-1236.
16. Wang Y, Bai Y, Qin L, Zhang P, Yi T, Teesdale SA, Zhao L, Pober JS, Tellides G. Interferon-gamma induces human vascular smooth muscle cell proliferation and intimal expansion by phosphatidylinositol 3-kinase dependent mammalian target of rapamycin raptor complex 1 activation. Circ Res. 2007;101:560-569.
17. Reinders ME, Sho M, Izawa A, Wang P, Mukhopadhyay D, Koss KE, Geehan CS, Luster AD, Sayegh MH, Briscoe DM. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest. 2003;112:1655-1665.
18. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59:99-106.
19. Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, Flasshove M, Ottmann OG, Jung W, Cavalli F, Kuse R, Thomalla J, Serve H, O'Farrell AM, Jacobs M, Brega NM, Scigalla P, Hossfeld DK, Berdel WE. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood. 2003;102:2763-2767.
20. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: roleofflt-1. Circ Res. 1998;83:832-840.
21. Banerjee S, Mehta S, Haque I, Sengupta K, Dhar K, Kambhampati S, Van Veldhuizen PJ, Banerjee SK. VEGF-A165 induces human aortic smooth muscle cell migration by activating neuropilin-1-VEGFR1-PI3K axis. Biochemistry. 2008;47:3345-3351.
22. Koga J, Matoba T, Egashira K, Kubo M, Miyagawa M, Iwata E, Sueishi K, Shibuya M, Sunagawa K. Soluble Flt-1 gene transfer ameliorates neointima formation after wire injury in flt-1 tyrosine kinase-deficient mice. Arterioscler Thromb Vasc Biol. 2009;29:458-464.
23. Tsuchihashi S, Ke B, Kaldas F, Flynn E, Busuttil RW, Briscoe DM, Kupiec-Weglinski JW. Vascular endothelial growth factor antagonist modulates leukocyte trafficking and protects mouse livers against ischemia/reperfusion injury. Am J Pathol. 2006;168:695-705.
24. Sho M, Akashi S, Kanehiro H, Hamada K, Kashizuka H, Ikeda N, Nomi T, Kuzumoto Y, Tsurui Y, Yoshiji H, Wu Y, Hicklin DJ, Briscoe DM, Nakajima Y. Function of the vascular endothelial growth factor receptors Flt-1 and Flk-1/KDR in the alloimmune response in vivo. Transplantation. 2005;80:717-722.
25. Raisky O, Nykanen AI, Krebs R, Hollmen M, Keranen MA, Tikkanen JM, Sihvola R, Alhonen L, Salven P, Wu Y, Hicklin DJ, Alitalo K, Koskinen PK, Lemstrom KB. VEGFR-1 and-2 regulate inflammation, myocardial angiogenesis, and arteriosclerosis in chronically rejecting cardiac allografts. Arterioscler Thromb Vasc Biol. 2007;27:819-825.
26. Zhao Q, Egashira K, Inoue S, Usui M, Kitamoto S, Ni W, Ishibashi M, Hiasa Ki K, Ichiki T, Shibuya M, Takeshita A. Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation. 2002;105:1110-1115.
27. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem. 2001;276:7614-7620.
28. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, Gabrilovich DI. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol. 1998;160:1224-1232.
29. Nakaki T, Nakayama M, Kato R. Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells. Eur J Pharmacol. 1990;189:347-353.
30. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA. 1995;92:1137-1141.
31. Kuzuya M, Satake S, Esaki T, Yamada K, Hayashi T, Naito M, Asai K, Iguchi A. Induction of angiogenesis by smooth muscle cell-derived factor: possible role in neovascularization in atherosclerotic plaque. J Cell Physiol. 1995;164:658-667.
32. Iijima K, Yoshikawa N, Connolly DT, Nakamura H. Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int. 1993;44:959-966.
33. Freeman MR, Schneck FX, Gagnon ML, Corless C, Soker S, Niknejad K, Peoples GE, Klagsbrun M. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res. 1995;55:4140-4145.
34. Iijima K, Yoshikawa N, Nakamura H. Activation-induced expression of vascular permeability factor by human peripheral T cells: a nonradioisotopic semiquantitative reverse transcription-polymerase chain reaction assay. J Immunol Methods. 1996;196:199-209.
35. Stavri GT, Hong Y, Zachary IC, Breier G, Baskerville PA, Yla-Herttuala S, Risau W, Martin JF, Erusalimsky JD. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett. 1995;358:311-315.
36. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87:3336-3343.
37. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities: implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem. 1996;271:17629-17634.
38. Boulday G, Haskova Z, Reinders ME, Pal S, Briscoe DM. Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-gammainducible protein of 10 kDa in vitro and in vivo. J Immunol. 2006;176:3098-3107.
39. Mor F, Quintana FJ, Cohen IR. Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol. 2004;172:4618-4623.
40. Shiao SL, Kirkiles-Smith NC, Shepherd BR, McNiff JM, Carr EJ, Pober JS. Human effector memory CD4+ T cells directly recognize allogeneic endothelial cells in vitro and in vivo. J Immunol. 2007;179:4397-4404.
41. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signaling: in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359-371.
42. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2): a reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem. 2001;276:3222-3230.
43. Shin JY, Yoon IH, Kim JS, Kim B, Park CG. Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells. Cell Immunol. 2009;256:72-78.
44. Byzova TV, Goldman CK, Pampori N, Thomas KA, Bett A, Shattil SJ, Plow EF. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell. 2000;6:851-860.
45. Tzima E, Irani-Tehrani M, Kiosses WB, Dejana E, Schultz DA, Engelhardt B, Cao G, DeLisser H, Schwartz MA. A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. Nature. 2005;437:426-431.
46. Jin ZG, Ueba H, Tanimoto T, Lungu AO, Frame MD, Berk BC. Ligandindependent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase. Circ Res. 2003;93:354-363.
47. Zhao Q, Egashira K, Hiasa K, Ishibashi M, Inoue S, Ohtani K, Tan C, Shibuya M, Takeshita A, Sunagawa K. Essential role of vascular endothelial growth factor and Flt-1 signals in neointimal formation after periadventitial injury. Arterioscler Thromb Vasc Biol. 2004;24:2284-2289.
48. Monaco C, Andreakos E, Kiriakidis S, Feldmann M, Paleolog E. T-cellmediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases. Curr Drug Targets Inflamm Allergy. 2004;3:35-42.